Impact of convalescent plasma therapy for treatment of Covid-19

Uzma Parveen, Salwa Mehrin, Mahvish Rana


Coronavirus SARS-CoV-2 is a leading cause of public health emergencies, particularly, has only few literatures have summarized its clinical and radiologic pattern, however the treatment strategies are confined, whilst it is   not just medical, economic and social but also has documented emphasis. Furthermore, the former Chinese guideline has highlighted that convalescent plasma (CP) therapy was a promising treatment for alarming Covid-19. CP is a pattern of passive immunization. Usually, CP was notoriously used to enhance the survival speed in a diverse outbreak such as SARS, MERS, influenza, Ebola virus disease, etc. It predominantly acts by neutralizing antibodies that  significantly bind to the specific antigens of SARS-CoV therein protecting the susceptibility of individuals, moreover, urgently needed to reduce the immediate health hazard  in this Covid-19 pandemic scenario. On the other hand, CP therapy is predominantly efficacious at the initial stage of disease ultimately confirmed by various research literature. This short review highlights on the use, historical context and its benefits in treatment of Covid-19.


Coronavirus, immunization, pandemic, emergencies, convalescent plasma

Full Text:



Winau F, Winu R. Emil von Behring and serum therapy. Microbes Infect 4:185-188, 2002.

Shakir EM, Cheung DS, Grayson MH. Mechanisms of immunotherapy: historical perspective. Ann Allergy Asthma Immunol 105:340-347, 2010.

Gillespie TR, Leendertz FH. COVID‐19: protect great apes during human pandemics. Nature 579(7800):497, 2020.

Jacobsen KH. Will COVID‐19 generate global preparedness? Lancet 395:1013‐1014, 2020

Banerjee A, Kulcsar K, Misra V, Frieman M, & Mossman K. Bats and Coronaviruses. Viruses 11:41, 2019.

Schoeman D & Fielding BC. Coronavirus envelope protein: current knowledge. Virology J 16:69, 2019.

M. Wang et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269-271, 2020.

World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID‐19 disease is suspected. Interim guidance 13 March 2020.

Rajendran K, Narayanasamy K, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review. J Med Virol 92:1475-1483, 2020.

Wong HK, Lee CK. Pivotal role of convalescent plasma in managing emerging infectious diseases. Vox Sang 115:545-547, 2020.

Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A, Al-Qahtani S, Al-Omari A, Al-Hameed F, Hayden FG. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis 22:1554, 2016.

Y. Cheng et al, Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24:44-46, 2005.

B. Zhou, N. Zhong, Y. Guan. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 357:1450-1451, 2007.

Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020.

L. Shang,J. Zhao, Y. Hu, R. Du, B. Cao, On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 395, 683-684, 2020.

Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 10: 676-678, 2004.

Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 38 (4 suppl):e66–e73, 2010.

Luke TC, Kilbane EM, Jackson JL, & Hoffman SL. Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? Annals Intern Med 145(8):599-609, 2006.

Chan JF, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes & Infect 9:221-236, 2020.

Walls AC, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181(2):281-292 e286, 2020.

Racine R & Winslow GM. IgM in microbial infections: taken for granted? Immunol letters 125(2):79-85, 2009.

Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 130:1545-1548, 2020.

Kai Duan et al. The feasibility of convalescent plasma therapy in severe COVID19 patients: a pilot study. medRxiv 2020.03.16.20036145.


  • There are currently no refbacks.